MARKET

SILO

SILO

Silo Pharma Inc
NASDAQ
6.05
+0.29
+4.95%
After Hours: 6.00 -0.04 -0.74% 19:36 06/26 EDT
OPEN
5.86
PREV CLOSE
5.76
HIGH
6.10
LOW
5.82
VOLUME
12.54K
TURNOVER
--
52 WEEK HIGH
15.15
52 WEEK LOW
3.315
MARKET CAP
6.82M
P/E (TTM)
-0.8112
1D
5D
1M
3M
1Y
5Y
1D
Psychedelic: Definium soars on study results for LSD-based depression treatment
TipRanks · 2d ago
Silo Pharma reports positive stability data for stress treatment SPC-15
TipRanks · 4d ago
Silo Pharma Confirms Nine‑Month Stability Of SPC‑15 Intranasal Prophylactic, Supporting IND‑Enabling CMC Documentation.
Benzinga · 4d ago
Silo Pharma reports SPC-15 PTSD nasal spray shows nine-month stability, supports Phase 1 trial plan
PUBT · 4d ago
SILO PHARMA REPORTS POSITIVE STABILITY DATA FOR SPC-15 PTSD TREATMENT, ADVANCING PROGRAM TOWARD FIRST-IN-HUMAN CLINICAL TRIAL
Reuters · 4d ago
Weekly Report: what happened at SILO last week (0615-0619)?
Weekly Report · 5d ago
Silo Pharma Regains Nasdaq Compliance, Stabilizing Listing Status
TipRanks · 06/19 00:38
Silo Pharma announces annual shareholder meeting
PUBT · 06/18 21:13
More
About SILO
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

Webull offers Silo Pharma Inc stock information, including NASDAQ: SILO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SILO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SILO stock methods without spending real money on the virtual paper trading platform.